Traders should anticipate continued negative sentiment due to the earnings miss; absence of financial detail in a so-called 'earnings release' raises transparency concerns. Monitor upcoming conference presentations for potential data updates.
XENE drugs
XENE drug pipeline →How the stock moved after the report
BEARISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Apr 15 $58.88entry
- T+1 · 7mo ago −0.76%α −1.02% · $58.43
- T+5 · 7mo ago −3.79%α −5.43% · $56.65
- T+20 · 6mo ago −6.59%α −12.63% · $55.00
- T+60 · 4mo ago +17.05%α +8.91% · $68.92
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Xenon Pharmaceuticals reported a Q4 2025 EPS miss of -9.4% versus consensus, with actual EPS at $-1.31 compared to an estimated $-1.20. The press release contains no financial results or operational updates, only investor conference announcements.
Key Financial Metrics
Key Facts
- Reported EPS of $-1.31 missed consensus estimate of $-1.20 by 9.4%, indicating worsening losses.
- No revenue or operating metrics were disclosed in the release; only investor event schedule was provided.
- Company announced upcoming presentations at four investor conferences in Q2 2026, but no new clinical or financial data.
Financial Impact
EPS miss of -9.4% implies deteriorating profitability; no revenue details provided
Risk Factors
- Lack of disclosed financials despite labeling as earnings context increases information asymmetry risk
- Biotech investors may interpret silence on pipeline progress as lack of near-term catalysts
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3274427 |
Track record
19 reports on XENE
2 of 4 bullish or bearish reports moved the stock their way by T+1. Best: +18.60% at T+60 after the Apr 19, 2026 report. 3 of 4 went positive at some point.
Filters
- Nov 16, 2026today SC 13G Neutral 3/10 Entry $40.11 Now $39.26 −2.12% settles Nov 17
- Nov 9, 20267d ago 8-K Neutral 5/10 Entry $41.39 to $42.10 Now $39.26 −5.15% ▲ +1.72% +0.40% vs SPY
- Nov 6, 202610d ago SC 13G/A Neutral 2/10 Entry $39.17 to $40.45 Now $39.26 +0.23% ▲ +3.27% +0.90% vs SPY
- Nov 6, 202610d ago SC 13G Neutral 4/10 Entry $39.17 to $40.45 Now $39.26 +0.23% ▲ +3.27% +0.90% vs SPY
- Nov 5, 202611d ago SC 13G/A Neutral 2/10 Entry $37.68 to $39.17 Now $39.26 +4.19% ▲ +3.95% +3.64% vs SPY
- Nov 3, 202613d ago Press Release Neutral 2/10 Entry $39.19 to $37.68 Now $39.26 +0.18% ▼ −3.85% +0.56% vs SPY
- Nov 3, 202613d ago Institutional Cluster Neutral 3/10 Entry $38.23 to $39.19 Now $39.26 +2.69% ▲ +2.51% +0.86% vs SPY
- Oct 1, 20266w ago Insider Cluster Bullish 6/10 Entry $38.93 to $38.02 Now $39.26 +0.85% ▼ −2.34% −3.08% vs SPY
- Jul 2, 202619w ago Press Release Neutral 1/10 Entry $60.96 to $60.54 Now $39.26 −35.60% ▼ −0.69% −1.56% vs SPY
- Jun 5, 202623w ago 144 Neutral 2/10 Entry $51.21 to $52.79 Now $39.26 −23.34% ▲ +3.09% +3.38% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers